Haverford Trust Co Buys Shares of 218,118 Thermo Fisher Scientific Inc. $TMO

Haverford Trust Co acquired a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the 2nd quarter, Holdings Channel.com reports. The institutional investor acquired 218,118 shares of the medical research company’s stock, valued at approximately $109,356,000. Thermo Fisher Scientific accounts for about 0.9% of Haverford Trust Co’s portfolio, making the stock its 26th largest holding.

Several other large investors have also recently made changes to their positions in TMO. North Dakota State Investment Board purchased a new stake in Thermo Fisher Scientific during the 4th quarter valued at about $7,505,000. BlackRock Inc. bought a new stake in Thermo Fisher Scientific in the second quarter valued at approximately $15,501,867,000. Hudson Value Partners LLC boosted its stake in shares of Thermo Fisher Scientific by 24.9% during the second quarter. Hudson Value Partners LLC now owns 16,653 shares of the medical research company’s stock valued at $8,349,000 after purchasing an additional 3,317 shares during the period. Xponance LLC grew its holdings in shares of Thermo Fisher Scientific by 8.1% in the fourth quarter. Xponance LLC now owns 59,295 shares of the medical research company’s stock worth $34,358,000 after purchasing an additional 4,436 shares during the last quarter. Finally, Annex Advisory Services LLC raised its holdings in Thermo Fisher Scientific by 12.6% during the 2nd quarter. Annex Advisory Services LLC now owns 24,656 shares of the medical research company’s stock valued at $12,361,000 after buying an additional 2,756 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $629.02 on Friday. The company has a market cap of $232.58 billion, a PE ratio of 33.84, a PEG ratio of 2.56 and a beta of 0.85. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $643.99. The firm’s 50-day moving average price is $542.53 and its 200-day moving average price is $509.70.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. During the same period last year, the firm earned $4.28 earnings per share. The company’s quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.11%.

Insider Activity at Thermo Fisher Scientific

In other news, VP Lisa P. Britt sold 11,440 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total value of $7,014,092.80. Following the sale, the vice president owned 14,784 shares in the company, valued at $9,064,366.08. This represents a 43.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Joseph R. Holmes sold 420 shares of the business’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the completion of the transaction, the chief accounting officer owned 2,966 shares of the company’s stock, valued at approximately $1,734,546.46. This represents a 12.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 63,493 shares of company stock valued at $37,657,681 over the last three months. Corporate insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on TMO. Weiss Ratings raised shares of Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, July 14th. Jefferies Financial Group reissued a “buy” rating and issued a $630.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Wolfe Research began coverage on Thermo Fisher Scientific in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 price objective for the company. Finally, Morgan Stanley upped their target price on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average target price of $619.41.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.